[go: up one dir, main page]

WO1992011025A3 - Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes - Google Patents

Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes Download PDF

Info

Publication number
WO1992011025A3
WO1992011025A3 PCT/US1991/009177 US9109177W WO9211025A3 WO 1992011025 A3 WO1992011025 A3 WO 1992011025A3 US 9109177 W US9109177 W US 9109177W WO 9211025 A3 WO9211025 A3 WO 9211025A3
Authority
WO
WIPO (PCT)
Prior art keywords
malignant proliferative
pulmonary diseases
alpha interferon
oral inhalation
treat asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/009177
Other languages
English (en)
Other versions
WO1992011025A2 (fr
Inventor
Robert J Spiegel
Francis M Cuss
Keith B Nolop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of WO1992011025A2 publication Critical patent/WO1992011025A2/fr
Publication of WO1992011025A3 publication Critical patent/WO1992011025A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composition pharmaceutique destinée au traitement ou à la prévention de l'asthme, ou au traitement ou à la prévention de maladies pulmonaires prolifératives non-malignes chez un mammifère. Le procédé consiste à administrer oralement par inhalation à un mammifère souffrant de l'asthme ou d'une telle maladie pulmonaire, c'est-à-dire un syndrome obstructif réversible des voies aériennes et/ou un brochospasme provoqué par l'exercise, une quantité efficace de rhIFN-α à l'aide d'un flacon nébuliseur ou d'un inhalateur-doseur.
PCT/US1991/009177 1990-12-21 1991-12-18 Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes Ceased WO1992011025A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63156590A 1990-12-21 1990-12-21
US63155290A 1990-12-21 1990-12-21
US631565 1990-12-21
US631552 1990-12-21

Publications (2)

Publication Number Publication Date
WO1992011025A2 WO1992011025A2 (fr) 1992-07-09
WO1992011025A3 true WO1992011025A3 (fr) 1992-09-17

Family

ID=27091422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/009177 Ceased WO1992011025A2 (fr) 1990-12-21 1991-12-18 Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes

Country Status (6)

Country Link
AU (1) AU9132091A (fr)
IE (1) IE914444A1 (fr)
IL (1) IL100415A0 (fr)
MX (1) MX9102702A (fr)
PT (1) PT99837A (fr)
WO (1) WO1992011025A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738838B2 (en) 1996-09-12 2001-09-27 Valentis, Inc. Compositions and methods for pulmonary gene delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248583A2 (fr) * 1986-05-27 1987-12-09 Schering Corporation Traitement intralésionnel de carcinomes de cellules basales par l'interféron-alpha humain recombinant
EP0266940A1 (fr) * 1986-10-22 1988-05-11 Schering Corporation Utilisation de l'alpha-interferon humain pour l'obtention d'un medicament pour le traitement du virus du SIDA
WO1988009673A1 (fr) * 1987-06-02 1988-12-15 Schering Corporation Traitement de l'hepatite b de type chronique avec une combinaison d'interferons alpha et gamma humains recombinants
EP0351974A1 (fr) * 1988-07-05 1990-01-24 Schering Corporation Traitement des verrues génitales avec un mélange de podophylline et recombinant DNA humain-alpha-interféron
EP0372809A1 (fr) * 1988-12-01 1990-06-13 Schering Corporation Médicament pour le traitement intralésionnel de carcinomes cellulaires squameux avec de l'interféron alpha humain recombinant
US4959210A (en) * 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248583A2 (fr) * 1986-05-27 1987-12-09 Schering Corporation Traitement intralésionnel de carcinomes de cellules basales par l'interféron-alpha humain recombinant
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0266940A1 (fr) * 1986-10-22 1988-05-11 Schering Corporation Utilisation de l'alpha-interferon humain pour l'obtention d'un medicament pour le traitement du virus du SIDA
WO1988009673A1 (fr) * 1987-06-02 1988-12-15 Schering Corporation Traitement de l'hepatite b de type chronique avec une combinaison d'interferons alpha et gamma humains recombinants
EP0351974A1 (fr) * 1988-07-05 1990-01-24 Schering Corporation Traitement des verrues génitales avec un mélange de podophylline et recombinant DNA humain-alpha-interféron
US4959210A (en) * 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
EP0372809A1 (fr) * 1988-12-01 1990-06-13 Schering Corporation Médicament pour le traitement intralésionnel de carcinomes cellulaires squameux avec de l'interféron alpha humain recombinant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 101, no. 17, 22 October 1984, (Columbus, Ohio, US), V. BOCCI et al.: "Pulmonary catabolism of interferons: alveolar absorption of 125I-labeled human interferon alpha is accompanied by partial loss of biological activity", see page 539, abstract no. 149518m, & ANTIVIRAL RES. 1984, 4(4), 211-20 (cited in the application) *

Also Published As

Publication number Publication date
IL100415A0 (en) 1992-09-06
AU9132091A (en) 1992-07-22
WO1992011025A2 (fr) 1992-07-09
PT99837A (pt) 1992-12-31
IE914444A1 (en) 1992-07-01
MX9102702A (es) 1992-06-01

Similar Documents

Publication Publication Date Title
IL112459A (en) Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases
Newman et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices
Sutton et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy.
CA2146954A1 (fr) Inhalateur active par la respiration
KR930701992A (ko) 환자의 폐에 잔존하는 점액 분비물의 제거 방법
Lin et al. Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction
Lofdahl et al. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction
Newhouse Principles of aerosol therapy
WO1992011025A3 (fr) Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes
Souëf The meaning of lung dose
GR3022083T3 (en) Inhalant based on taurine
Borgström The importance of the device in asthma therapy
Kirby et al. Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.
Brosch et al. Anesthetic Management of the Asthmatic Patient with Special Reference to the Use of Ketamine
Steed et al. The oropharyngeal and lung deposition patterns of a fusafungine MDI spray delivered by HFA 134a propellant or by CFC 12 propellant
Matthys Chlorofluorocarbon-free aerosol therapy in patients with pulmonary airflow obstruction
Lahdensuo Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis
Gorbach et al. Therapeutic potentialities of rifampicin-dimexid inhalations in phthisiopulmonology.
Alderson et al. Pediatric Aerosol Therapy Guidelines: Indications, Techniques, and Dosages
Leigh et al. The use of inhaled radioisotopes for measuring the effect of sputum induction on tracheobronchial clearance rates
Wolyniec et al. BI-L-239, a 5-lipoxygenase inhibitor, blocks inhaled antigen-induced airway hyperresponsiveness in conscious guinea pigs
Nieminen et al. Equivalent clinical effectiveness of old and new models of Easyhaler
Brosch et al. Vortrag Nr. 164 ANESTHETIC MANAGEMENT OF THE ASTHMATIC PATIENT WITH SPECIAL REference TO THE USE OF KETAMINE
Rogers Combined inhalation of cromolyn sodium and metaproterenol sulfate in life-threatening asthma.
Hidinger et al. Bronchodilator effect of terbutaline aerosol is not affected by propellant vapour pressure or dose volume

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA